Icosavax logo

Icosavax

Public Company
Seattle

Icosavax develops virus-like particle vaccines targeting respiratory viruses such as RSV, hMPV, and COVID-19. Its platform uses computational protein design and virus-like particle scaffolds to create experimental vaccines intended to be shelf-stable and advance to clinical trials.

Facts

HQ
Seattle
Sectors
Biotechnology, Vaccines, Life Sciences
Status
Public Company
Stage
Public
Members see funding amounts.
.

Is this your organization? Claim it

UW Institute for Protein Design and Nvidia open-source RFD4-Proteina model, claims 5–10× faster designs and higher success rates

The UW Medicine Institute for Protein Design and Nvidia released RFD4-Proteina, an open-source AI model that co-designs protein sequences and atomic structures and reportedly produces candidates 5–10× faster with 5–10× higher benchmark success rates. A UW student used the model to design an improved pesticide-degrading enzyme in days, and lab tests confirmed the model's outputs behaved as expected.

UW Institute for Protein Design and Nvidia unveil RFD4-Proteina, an open-source AI model for designing functional proteins after Jensen Huang GPU grant

UW’s Institute for Protein Design and Nvidia jointly released RFD4-Proteina, an open-source AI model for designing proteins with specific functions, developed after a major GPU grant from Nvidia CEO Jensen Huang’s foundation. IPD and director David Baker say the model is faster, more efficient, and could enable new medical, sustainability, and biotechnology applications.

See all 31 stories, episodes and videos about Icosavax.

People